Drug may give cells a fresh start
“Chemists in California have found a synthetic molecule that seems to reprogramme adult cells to make them more like youthful ones. If the discovery pans out, it could provide an easy source of cells to regenerate tissues damaged by disease or injury.”
On thin ice: how the quest for a billion-dollar microbe is running out of control in Earth’s last wilderness
A new UN study implies that searching for exremeophiles in areas such as the Antarctic “is threatening to plunder the planet’s last wilderness.” The body of the report, however, seems to focus on intellectual property issues.
While are cases where pharmaceutical companies have patented indigenous products (eg. neem), there are no Antarctic natives! The aim of the report seems to be to establish guidelines to level the playing field, because “ethical companies felt they could not assert their intellectual property rights with government agencies.”
I’m not sure I really understand what any of this has to do with plundering the wilderness. Seems more like the sort of crisis-by-equivocation that the United Nations is famous for.
Management issues challenge biotech startups
This article reviews a very interesting report that basically faults the failure of biotechnology companies to successfuly transition from research focus to product development and commercialization on hiring managers with a scientific rather than managerial forte and aiming to pass regulatory hurdles rather than build a company.
Industry observations certainly support this thesis. It’s nice to see that the effort has been made to examine and document it.
Monsanto: Ready to Blossom?
Shifting the focus from farm chemicals to the more lucrative gene-altered seeds hasn’t been easy, but the effort could pay off big.
FDA big factor behind high US drug costs
The U.S. Food and Drug Administration, with its costly and time-consuming drug approval process, is a big reason Americans pay far more for medicine than consumers in the rest of the world, U.S. Nobel laureate Milton Friedman said Tuesday.
FDA Begins Push to End Drug Imports
A second ‘blitz’ inspection by federal drug and customs officials of medicines imported from Canada has found that nearly all of the almost 2,000 packages opened contained foreign versions of American pharmaceuticals that officials said might not be safe.
What To Expect From A Venture Capitalist
The more important question is, ‘What can I expect out of a good venture capitalist?’ The answer to this is: five hours per month of mindshare during which he opens doors for you with prospective customers and partners and interviews candidates for high-level positions at your company.
Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth
What’s in a Drug Name?
Did you ever wonder at the bizarre brand names born by your favorite medicines? If so, you’ve probably guessed brand-name rule No. 1: They don’t actually mean anything.
Rise in biotech lawsuits
Biotech companies were served with 17 percent of all U.S. shareholder suits last year, according to PricewaterhouseCoopers’ Securities Litigation Study of 2003.
By contrast, biotech’s estimated 350 public companies make up only 2 percent of the approximately 17,000 firms publicly traded in the United States.